Coronavirus Disease 2019 (COVID-19) Impact on Publicly Traded Bio/Pharma Companies
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization.
Scope
This 34-page PowerPoint based report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.
F. Hoffmann-La Roche Ltd
Novartis AG
Merck & Co Inc
Pfizer Inc
Bristol-Myers Squibb Co
Amgen Inc
AbbVie Inc
AstraZeneca Plc
Eli Lilly and Co
Sanofi
GlaxoSmithKline Plc
Novo Nordisk AS
CSL Ltd
Gilead Sciences Inc
Bayer AG
Allergan Plc
Vertex Pharmaceuticals Inc
Biogen Inc
Regeneron Pharmaceuticals Inc
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.